Do analysts prefer AEON or FBLG?

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' higher probable upside, analysts clearly believe FibroBiologics is more favorable than AEON Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, AEON or FBLG?

FibroBiologics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AEON Biopharma N/A N/A -$36.63M -$5.00 N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is AEON or FBLG more profitable?

AEON Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets AEON Biopharma N/A N/A -994.63% FibroBiologics N/A -767.07% -195.56%

Does the media prefer AEON or FBLG?

In the previous week, AEON Biopharma and AEON Biopharma both had 3 articles in the media. FibroBiologics' average media sentiment score of 0.88 beat AEON Biopharma's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBLG or ALLR more profitable?

Allarity Therapeutics' return on equity of -109.94% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% Allarity Therapeutics N/A -109.94% -47.27%

Does the media refer more to FBLG or ALLR?

In the previous week, FibroBiologics and FibroBiologics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.96 beat FibroBiologics' score of 0.88 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, FBLG or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$6.93 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is FBLG or AKTX more profitable?

Akari Therapeutics' return on equity of -123.29% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% Akari Therapeutics N/A -123.29% -63.01%

Does the media refer more to FBLG or AKTX?

In the previous week, FibroBiologics and FibroBiologics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 1.29 beat FibroBiologics' score of 0.88 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBLG or HOWL more profitable?

Werewolf Therapeutics' return on equity of -208.23% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% Werewolf Therapeutics N/A -208.23% -75.12%

Does the media refer more to FBLG or HOWL?

In the previous week, Werewolf Therapeutics had 1 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 3 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.88 beat Werewolf Therapeutics' score of 0.28 indicating that FibroBiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Werewolf Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GTBP or FBLG?

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, GTBP or FBLG?

FibroBiologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is GTBP or FBLG more profitable?

GT Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% FibroBiologics N/A -767.07% -195.56%

FibroBiologics (FBLG) Competitors

$0.84 -0.01 (-1.03%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.02 (+1.92%)

As of 07/15/2026 07:03 PM Eastern

Compare

FBLG vs. AEON, ALLR, AKTX, HOWL, and GTBP

Should you buy FibroBiologics stock or one of its competitors? MarketBeat compares FibroBiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FibroBiologics include AEON Biopharma (AEON), Allarity Therapeutics (ALLR), Akari Therapeutics (AKTX), Werewolf Therapeutics (HOWL), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry.

How does FibroBiologics compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

FibroBiologics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, AEON Biopharma and AEON Biopharma both had 3 articles in the media. FibroBiologics' average media sentiment score of 0.88 beat AEON Biopharma's score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AEON Biopharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

AEON Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
FibroBiologics	N/A	-767.07%	-195.56%

22.8% of AEON Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Comparatively, 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' higher probable upside, analysts clearly believe FibroBiologics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

AEON Biopharma beats FibroBiologics on 7 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Allarity Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

11.5% of Allarity Therapeutics shares are held by institutional investors. 9.3% of FibroBiologics shares are held by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, FibroBiologics and FibroBiologics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.96 beat FibroBiologics' score of 0.88 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FibroBiologics presently has a consensus target price of $74.00, indicating a potential upside of 8,680.26%. Allarity Therapeutics has a consensus target price of $10.25, indicating a potential upside of 768.64%. Given FibroBiologics' higher probable upside, equities research analysts plainly believe FibroBiologics is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

FibroBiologics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Allarity Therapeutics' return on equity of -109.94% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Allarity Therapeutics has higher revenue and earnings than FibroBiologics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Allarity Therapeutics	$320K	58.67	-$11.23M	-$0.72	N/A

Summary

Allarity Therapeutics beats FibroBiologics on 7 of the 11 factors compared between the two stocks.

How does FibroBiologics compare to Akari Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, FibroBiologics and FibroBiologics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 1.29 beat FibroBiologics' score of 0.88 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akari Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

FibroBiologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Akari Therapeutics' return on equity of -123.29% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Akari Therapeutics	N/A	-123.29%	-63.01%

5.1% of Akari Therapeutics shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

FibroBiologics currently has a consensus price target of $74.00, indicating a potential upside of 8,680.26%. Akari Therapeutics has a consensus price target of $89.00, indicating a potential upside of 637.37%. Given FibroBiologics' higher probable upside, research analysts clearly believe FibroBiologics is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akari Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

Summary

Akari Therapeutics beats FibroBiologics on 9 of the 10 factors compared between the two stocks.

How does FibroBiologics compare to Werewolf Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Werewolf Therapeutics' return on equity of -208.23% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Werewolf Therapeutics	N/A	-208.23%	-75.12%

FibroBiologics presently has a consensus target price of $74.00, indicating a potential upside of 8,680.26%. Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 1,004.57%. Given FibroBiologics' higher possible upside, research analysts clearly believe FibroBiologics is more favorable than Werewolf Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

64.8% of Werewolf Therapeutics shares are held by institutional investors. 9.3% of FibroBiologics shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

FibroBiologics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

FibroBiologics has higher earnings, but lower revenue than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Werewolf Therapeutics	$1.88M	8.78	-$60.82M	-$1.24	N/A

In the previous week, Werewolf Therapeutics had 1 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 3 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 0.88 beat Werewolf Therapeutics' score of 0.28 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Werewolf Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Werewolf Therapeutics beats FibroBiologics on 9 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to GT Biopharma?

GT Biopharma (NASDAQ:GTBP) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

FibroBiologics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, FibroBiologics had 2 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.91 beat FibroBiologics' score of 0.88 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Very Positive
FibroBiologics	Positive

GT Biopharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

GT Biopharma's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
FibroBiologics	N/A	-767.07%	-195.56%

8.2% of GT Biopharma shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by insiders. Comparatively, 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

FibroBiologics beats GT Biopharma on 7 of the 13 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.18M	$3.65B	$6.78B	$12.56B
Dividend Yield	N/A	2.22%	2.68%	9.45%
P/E Ratio	-0.12	21.32	27.08	24.35
Price / Sales	N/A	178.33	487.44	76.04
Price / Cash	N/A	143.89	48.63	60.00
Price / Book	0.46	8.56	10.82	6.31
Net Income	-$18.65M	$23.88M	$3.59B	$331.55M
7 Day Performance	-2.11%	-3.25%	-1.80%	-0.71%
1 Month Performance	4.05%	7.59%	3.71%	0.16%
1 Year Performance	-94.15%	49.87%	27.41%	19.66%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	2.6123 of 5 stars	$0.84 -1.0%	$74.00 +8,680.3%	-94.0%	$5.18M	N/A	N/A	10	Gap Down
AEON AEON Biopharma	0.749 of 5 stars	$0.71 -3.0%	N/A	-62.5%	$17.92M	N/A	3.93	5	News Coverage Gap Down
ALLR Allarity Therapeutics	2.4964 of 5 stars	$1.10 -8.3%	$10.25 +831.8%	+16.8%	$17.50M	$320K	N/A	10	Short Interest Decrease
AKTX Akari Therapeutics	3.0677 of 5 stars	$15.12 +38.7%	$89.00 +488.6%	-72.3%	$17.24M	N/A	N/A	9	Positive News Short Interest Decrease Gap Down
HOWL Werewolf Therapeutics	3.4624 of 5 stars	$0.34 +7.2%	$3.75 +993.3%	-74.1%	$16.67M	$1.88M	N/A	40	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. AEON, ALLR, AKTX, HOWL, and GTBP

How does FibroBiologics compare to AEON Biopharma?

Summary

How does FibroBiologics compare to Allarity Therapeutics?

Summary

How does FibroBiologics compare to Akari Therapeutics?

Summary

How does FibroBiologics compare to Werewolf Therapeutics?

Summary

How does FibroBiologics compare to GT Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. AEON, ALLR, AKTX, HOWL, and GTBP

How does FibroBiologics compare to AEON Biopharma?

Which has higher valuation and earnings, AEON or FBLG?

Does the media prefer AEON or FBLG?

Which has more risk and volatility, AEON or FBLG?

Is AEON or FBLG more profitable?

Do insiders and institutionals believe in AEON or FBLG?

Do analysts prefer AEON or FBLG?

Summary

How does FibroBiologics compare to Allarity Therapeutics?

Do institutionals & insiders have more ownership in FBLG or ALLR?

Does the media refer more to FBLG or ALLR?

Do analysts recommend FBLG or ALLR?

Which has more risk & volatility, FBLG or ALLR?

Is FBLG or ALLR more profitable?

Which has higher valuation & earnings, FBLG or ALLR?

Summary

How does FibroBiologics compare to Akari Therapeutics?

Does the media refer more to FBLG or AKTX?

Which has more risk and volatility, FBLG or AKTX?

Is FBLG or AKTX more profitable?

Do insiders & institutionals have more ownership in FBLG or AKTX?

Do analysts recommend FBLG or AKTX?

Which has preferable earnings and valuation, FBLG or AKTX?

Summary

How does FibroBiologics compare to Werewolf Therapeutics?

Is FBLG or HOWL more profitable?

Do analysts rate FBLG or HOWL?

Do insiders and institutionals have more ownership in FBLG or HOWL?

Which has more volatility & risk, FBLG or HOWL?

Which has stronger valuation & earnings, FBLG or HOWL?

Does the media refer more to FBLG or HOWL?

Summary

How does FibroBiologics compare to GT Biopharma?

Which has higher earnings & valuation, GTBP or FBLG?

Do analysts prefer GTBP or FBLG?

Does the media prefer GTBP or FBLG?

Which has more risk & volatility, GTBP or FBLG?

Is GTBP or FBLG more profitable?

Do institutionals & insiders have more ownership in GTBP or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools